<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="36704">Imiquimod</z:chebi> 5% cream has been used effectively to treat superficial <z:hpo ids='HP_0002671'>basal cell carcinomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: The purpose of this study is to examine the effectiveness, tolerability, and desirability of <z:chebi fb="0" ids="36704">imiquimod</z:chebi> 5% cream in treating superficial non-facial <z:hpo ids='HP_0002671'>basal cell carcinomas</z:hpo> in a patient with <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Three biopsy-proven nonfacial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> were treated for 18 weeks with once daily application of 5% <z:chebi fb="0" ids="36704">imiquimod</z:chebi> cream </plain></SENT>
<SENT sid="3" pm="."><plain>The lesions were then removed to search histologically for <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The two adequately treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> revealed no residual <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> upon removal </plain></SENT>
<SENT sid="5" pm="."><plain>Our patient reported that he tolerated the treatment but he would not desire this treatment again based on the length of treatment time and the degree of local <z:mp ids='MP_0001845'>inflammation</z:mp> at the treatment sites </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="36704">Imiquimod</z:chebi> 5% cream appears to be effective in eradicating superficial nonfacial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The degree of local <z:mp ids='MP_0001845'>inflammatory response</z:mp> may affect the patients' tolerability of treatment and therefore patient compliance </plain></SENT>
</text></document>